AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03281200
Drug: L01XE31 - Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: L01XE31 - Nintedanib
Trial: NCT04778137
Drug: Omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Biological: CMAB007 Biological: Xolair
Trial: NCT00483977
Drug: Oxycodone
RxNorm normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks
Trial: NCT00483977
Drug: PF-000592379
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-00592379: oral, 30 mg, once a day for 2 weeks
Trial: NCT00612144
Drug: Glimepiride/metformin fixed combination
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amaryl M 1/250mg\~4/1000mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG
Trial: NCT00612144
Drug: Metformin HCl
RxNorm normalized name: metformin HCl
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin HCl 500mg\~1250mg bid for 12\~26 weeks~* Maintenance dose for 10 weeks after 2\~14 weeks of dose titration~* Dose titration according to titration algorithm based on daily mean SMBG
Trial: NCT01526733
Drug: Sham Injection
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01526733
Drug: Recombinant human hyaluronidase PH20
RxNorm normalized name: PEGylated recombinant human hyaluronidase PH20
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01526733
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01526733
Drug: Insulin lispro
RxNorm normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01138449
Drug: Vitamin A
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil, orally as a single dose to neonates on the day of birth or in the next 2 days of birth keeping a minimum period of 2 hours between the birth and the dosing
Trial: NCT04355169
Drug: Naldemedine
RxNorm normalized name: Naldemedine
DrugBank: Naldemedine (DB11691)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablet
Trial: NCT00135551
Drug: Angiotensin receptor blockers
RxNorm normalized name: ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: benidipine+angiotensin receptor blocker, titlation scheme
Trial: NCT00135551
Drug: β-blockers
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: benidipine+β-blockers, titlation scheme
Trial: NCT01444040
Drug: Travoprost
RxNorm normalized name: Travoprost
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Travoprost drops
Trial: NCT03136510
Drug: Apixaban 5 mg
RxNorm normalized name: apixaban 5 MG
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bood collection for biological analyses at:~* inclusion visit~* follow-up visit at 1 month~* end of research at 3 month
Trial: NCT00043862
Drug: topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01931566
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone SR tablets
Trial: NCT01931566
Drug: Pioglitazone placebo
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone placebo-matching tablets
Trial: NCT00659789
Drug: Vacc-4x
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
Trial: NCT00659789
Drug: Sterile water
RxNorm normalized name: sterile water
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile water is used in place of Vacc-4x and in place of Leukine
Trial: NCT02721966
Drug: Secukinumab and Placebo
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Placebo matching AIN457
Trial: NCT02979548
Drug: Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant is a non peptide, selective, Neurokinin type 1 (NK 1) receptor antagonist. Group A will receive Aprepitant as an add-on anti-emetic therapy in addition to ondansetron.
Trial: NCT02979548
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron is 5HT3 Receptor antagonist used to treat and prevent chemotherapy induced nausea and vomiting
Trial: NCT02979548
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine receptor antagonist , acts at CTZ. Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
Trial: NCT03008369
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01694797
Drug: Metoprolol Succinate
RxNorm normalized name: Metoprolol Succinate
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03714880
Drug: Mifepristone 200 MG
RxNorm normalized name: mifepristone 200 MG
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ingestion of study medication vs placebo
Trial: NCT00559819
Drug: Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%
Trial: NCT00174486
Drug: Cialis (Tadalafil)
RxNorm normalized name: Cialis
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01809743
Drug: Regadenoson central -central
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
Trial: NCT01809743
Drug: Regadenoson peripheral - peripheral
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
Trial: NCT01809743
Drug: Regadenoson central - peripheral
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
Trial: NCT01809743
Drug: Regadenoson peripheral - central
RxNorm normalized name: Regadenoson
DrugBank: Regadenoson (DB06213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
Trial: NCT02139007
Drug: Alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01497561
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
Trial: NCT00241436
Drug: Anastrozole (ARIMIDEX™)
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00828204
Drug: BG9418 (interferon beta-1a)
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02863120
Drug: liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02863120
Drug: bupivacaine HCl
RxNorm normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02863120
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02863120
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00308490
Drug: iron sucrose
RxNorm normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04239014
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 300 mg BD (2 × 150 mg tablets) continually in the olaparib monotherapy and ceralasertib+olaparib treatment arms.
Trial: NCT04239014
Drug: Ceralasertib
RxNorm normalized name: Ceralasertib
DrugBank: Ceralasertib (DB14917)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceralasertib 160 mg QD (2 × 80 mg tablets) from Days 1 to 7 (inclusive) of every 28-day cycle.
Trial: NCT04239014
Drug: Placebo to match olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Per olaparib
Trial: NCT04960657
Drug: glibenclamide
RxNorm normalized name: Glibenclamide
DrugBank: Glyburide (DB01016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of glibenclamide/placebo. To investigate the role of PACAP38 on cranial arteries in healthy volunteers after glibenclamide/placebo administration .
Trial: NCT04960657
Drug: PACAP38
DrugBank: PACAP38 (DB17073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PACAP38 infusion
Trial: NCT04139213
Drug: buprenorphine/naloxone oral product
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: To treat opioid use disorder, buprenorphine/naloxone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a weekly or monthly basis, unless the care plan specifies greater frequency of pharmacy visit. The median expected dose of buprenorphine/naloxone (sublingual film or tablet) is 8 to 24 mg daily, and may be adjusted per the collaborative pharmacy practice agreement.
Trial: NCT04139213
Drug: injectable naltrexone
RxNorm normalized name: naltrexone Injection
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To treat opioid use disorder, injectable naltrexone will be provided by a study pharmacist under a collaborative pharmacy practice agreement on a monthly (injectable naltrexone) basis. The expected dose of injectable naltrexone will be approximately 380 mg. Injectable naltrexone will be dispensed and prepared by the pharmacist but administered by nursing staff for the pilot study.
Trial: NCT04139213
Drug: oral naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To augment care for patients receiving injectable naltrexone for the treatment of OUD and treat cravings that may arise before their scheduled injection, patients prescribed injectable naltrexone may be provided a several day supply of oral naltrexone by a study pharmacist under a collaborative pharmacy practice agreement. The expected dose of oral naltrexone will be approximately 25-50 mg daily.
Trial: NCT00057720
Drug: TLK286 HCl for injection
RxNorm normalized name: Colestipol Hydrochloride for Oral Suspension
DrugBank: Colestipol (DB00375)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00057720
Drug: topotecan hydrochloride for injection
RxNorm normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00696332
Drug: Talampanel
RxNorm normalized name: Talampanel
DrugBank: Talampanel (DB04982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules Talampanel, 3 times per day, 52 weeks
Trial: NCT01287741
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab at a dose of 375 mg/m\^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles.
Trial: NCT01287741
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15.
Trial: NCT01287741
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
Trial: NCT01287741
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
Trial: NCT06654570
Drug: Intravaginal estrogen during adjuvant letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postmenopausal patients undergoing adjuvant letrozole therapy and experiencing VVA symptoms were treated with vaginal estradiol for 12 weeks. Gynecologic examination and symptom screening were conducted at baseline and after 12 weeks. Serum E2 levels were analyzed at baseline, and at two, four, eight, and 12 weeks. E2 levels were measured using both a routine liquid chromatography-tandem mass spectrometry (LC-MS/MS) method and a highly sensitive (hsE2-MS) LC-MS/MS method.
Trial: NCT02930018
Drug: Nerinetide (NA-1), 2.6 mg/kg
DrugBank: Nerinetide (DB12595)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous infusion of nerinetide over 10 ± 1 minutes
Trial: NCT01518894
Drug: PF-04958242
RxNorm normalized name: PF-04958242
DrugBank: PF-04958242 (DB11843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04958242 0.10 mg oral solution Q24 hours for 14 days
Trial: NCT01518894
Drug: PF-04958242
RxNorm normalized name: PF-04958242
DrugBank: PF-04958242 (DB11843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04958242 0.20 mg oral solution Q24 hours for 14 days
Trial: NCT01518894
Drug: PF-04958242
RxNorm normalized name: PF-04958242
DrugBank: PF-04958242 (DB11843)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)
Trial: NCT03194594
Drug: Ketamine Hydrochloride, dexamethasone, and combination of two drugs
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.
Trial: NCT00161031
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03085940
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 400mg once daily initially
Trial: NCT00088023
Drug: PT-523 for Injection
RxNorm normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00031616
Drug: brivudine phosphoramidate
RxNorm normalized name: Brivudine phosphoramidate
DrugBank: Thymectacin (DB05116)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01987453
Drug: RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)~Participants in the LDV/SOF+RBV 24 weeks group will dose adjust RBV according to hemoglobin and renal status as stated in the RBV package insert.
Trial: NCT02181543
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1μg/Kg, IV (in the vein) intraoperative. Number of Cycles: single dose.
Trial: NCT00198107
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 kg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.
Trial: NCT00198107
Drug: D-cycloserine
RxNorm normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D-cycloserine will be dosed in the range of 25 to 200 mg daily for the final 8 weeks of treatment.
Trial: NCT00934661
Drug: Extended Release Epidural Morphine (EREM)
RxNorm normalized name: morphine Extended Release Oral Tablet
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single Four mg (0.4 ml)dose of EREM will be administered into the epidural space and flushed with 1 ml of saline
Trial: NCT00602082
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00602082
Drug: streptozocin
RxNorm normalized name: Streptozocin
DrugBank: Streptozocin (DB00428)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04537286
Drug: nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel 125 mg/m2，ivgtt，d1, 8 Cisplatin 75 mg/m2，ivgtt，d1 Carilizumab 200mg, ivgtt，d1，q2w
Trial: NCT00116610
Drug: picoplatin
RxNorm normalized name: Picoplatin
DrugBank: Picoplatin (DB04874)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00809718
Drug: Raltegravir and rifapentine
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Period 1- Raltegravir 400 mg q12h by mouth for 4 days~Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days~Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days
Trial: NCT02415413
Drug: carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02415413
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02415413
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02415413
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00309491
Drug: Tamoxifen alone
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 20 mg tamoxifen daily, start of therapy within 4 weeks after surgery; therapy duration 5 years
Trial: NCT00309491
Drug: Tamoxifen + Aminoglutethimide
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 x 20 mg tamoxifen daily (5 years) plus Aminoglutethimide daily (first 2 years)~* 1st therapy week:125mg/-/125mg Aminoglutethimide daily~* 2nd therapy week: 125mg/-/250mg Aminoglutethimid daily~* as of 3rd therapy week: 250mg/-/250mg Aminoglutethimid daily
Trial: NCT02336529
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02336529
Drug: NaCl
RxNorm normalized name: NaCl
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00846976
Drug: Bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg daily
Trial: NCT00364104
Drug: Ferrous sulfate
RxNorm normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-weeks of iron supplementation only plus 10-days matching placebo of Hp infection eradication therapy
Trial: NCT04626908
Drug: GC022F CAR-T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject receive GC022F CAR-T cells by intravenous infusion
Trial: NCT02132429
Drug: AMG 333
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration available in varying dose strength.
Trial: NCT02644421
Drug: VVZ-149
RxNorm normalized name: Vvz-149 free base
DrugBank: Opiranserin (DB16271)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02644421
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no